The purpose of this study is to evaluate the safety and tolerability of an experimental drug called AVZO-1418 for the treatment of locally advanced solid tumors (cancers that have grown to a serious stage and form solid lumps in the body) or metastatic solid tumors (cancers that have spread from their original site to other parts of the body and form solid lumps). AVZO-1418 will be tested alone or in combination with other drugs (pembrolizumab or osimertinib) to determine the best dose of AVZO-1418 to continue using in this study and future studies. Researchers also aim to learn whether the drugs can help treat advanced or metastatic solid tumors and how the body absorbs, distributes, and gets rid of AVZO-1418. In addition, the study will examine whether the immune system reacts to these drugs and how AVZO-1418 functions in the body. AVZO-1418 works by blocking specific receptors on the cancer cell, leading to the death of the cancer cell. Pembrolizumab is a type of medication called an immunotherapy, which strengthens the immune system or helps the immune system to find cancer cells and attack them. Osimertinib works by blocking specific genetic mutations (EGFR mutations) in lung cancer cells to stop their growth. Pembrolizumab and osimertinib are approved by the U.S. Food and Drug Administration (FDA) for the treatment of various types of cancers, but their use in this study is considered experimental.

• CS Cancer at Cedars-Sinai Medical Center : Shannon Cyhan
• CS Cancer at The Angeles Clinic and Research Institute : Shannon Cyhan